|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Melanocytic nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations.
|
3891875 |
1985 |
|
Dysplastic Nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Erythema Chronicum Migrans
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Glossitis, Benign Migratory
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the sequence had a high degree of similarity to the peptidoglycan-associated outer membrane lipoprotein P6 of Haemophilus influenzae and the peptidoglycan-associated lipoprotein PAL of E. coli.
|
8576327 |
1995 |
|
Myofibromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunocytochemistry (Ulex, factor VIII, JC/70A [CD31], PAL-E, BMA120, EN4, QBEnd10 [CD34], SMS actin) and ultrastructural studies showed no (marked) differences between different types of IMF.
|
8600777 |
1995 |
|
Infantile myofibromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunocytochemistry (Ulex, factor VIII, JC/70A [CD31], PAL-E, BMA120, EN4, QBEnd10 [CD34], SMS actin) and ultrastructural studies showed no (marked) differences between different types of IMF.
|
8600777 |
1995 |
|
Hyperphenylalaninaemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We describe (i) an efficient recombinant approach to produce PAL enzyme, (ii) testing of PAL in orthologous N-ethyl-N'-nitrosourea (ENU) mutant mouse strains with HPA, and (iii) proofs of principle (PAL reduces HPA)-both pharmacologic (with a clear dose-response effect vs. HPA after PAL injection) and physiologic (protected enteral PAL is significantly effective vs. HPA).
|
10051643 |
1999 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
|
Ankylosing spondylitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
|
Hemangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By contrast, blood vessel endothelium and hemangiomas were strongly positive for PAL-E and CD34 but were mostly negative for CD9 and podoplanin.
|
14559986 |
2003 |
|
Lymphangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regular lymphatic endothelium and lymphangiomas were strongly positive for CD9 and podoplanin but were mostly negative for PAL-E and CD34.
|
14559986 |
2003 |
|
Neoplasms, Vascular Tissue
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Using immunohistochemistry, expression of CD9 was studied in 17 samples of head and neck mucosa and skin (laryngeal mucosa: n = 2, oral: n = 6, and epidermis: n = 9) and a variety of vascular tumors (lymphangiomas: n = 9, juvenile nasopharyngeal angiofibromas: n = 4, hemangiomas: n = 7, angiosarcomas: n = 5, and Kaposi's sarcomas: n = 7) and compared with the expression of CD34 and PAL-E (blood vessel markers) and the lymphatic marker podoplanin.
|
14559986 |
2003 |
|
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry, expression of CD9 was studied in 17 samples of head and neck mucosa and skin (laryngeal mucosa: n = 2, oral: n = 6, and epidermis: n = 9) and a variety of vascular tumors (lymphangiomas: n = 9, juvenile nasopharyngeal angiofibromas: n = 4, hemangiomas: n = 7, angiosarcomas: n = 5, and Kaposi's sarcomas: n = 7) and compared with the expression of CD34 and PAL-E (blood vessel markers) and the lymphatic marker podoplanin.
|
14559986 |
2003 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We also discuss the possible involvement of the PAL-mechanism in carcinogenesis.
|
15970690 |
2005 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Secondary endpoints include the Hospital Anxiety and Depression Scale, Short form McGill Pain Questionnaire-2, European Organization for Research and Treatment of Cancer QLQ-C15-PAL, Pain Catastrophizing Scale, and adverse events, Eligibility criteria are patients with advanced carcinoma with non-daily use of opioids in initial screening for registration; and cancer pain targeted for daily opioid treatment, NSAIDs or acetaminophen, NRS ≥3(average over 24 h), opioid-treatment naive within 30 h, no chemotherapy, radiotherapy, or bisphosphonate administration newly started within 2 weeks, and written informed consent at the time of second registration.
|
28985716 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Secondary endpoints include the Hospital Anxiety and Depression Scale, Short form McGill Pain Questionnaire-2, European Organization for Research and Treatment of Cancer QLQ-C15-PAL, Pain Catastrophizing Scale, and adverse events, Eligibility criteria are patients with advanced carcinoma with non-daily use of opioids in initial screening for registration; and cancer pain targeted for daily opioid treatment, NSAIDs or acetaminophen, NRS ≥3(average over 24 h), opioid-treatment naive within 30 h, no chemotherapy, radiotherapy, or bisphosphonate administration newly started within 2 weeks, and written informed consent at the time of second registration.
|
28985716 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Fifty-two patients who received a single 8-Gy RT for painful bone metastases completed the EORTC QOL-C15-PAL questionnaire prior to randomization and at 42-day post RT.
|
29156910 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) bone metastases module (QLQ-BM22) and EORTC QOL Core-15-Palliative (QLQ-C15-PAL) before treatment and at days 10 and 42 after a single 8 Gy radiation treatment.
|
29156903 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
|
Phenylketonurias
|
0.030 |
Biomarker
|
group |
BEFREE |
Phenylalanine ammonia lyase from Anabaena variabilis (Av-PAL) is a candidate for the treatment of phenylketonuria (PKU).
|
28343264 |
2017 |